melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling
Melior Discovery
home
Our Services
High Throughput In Vivo Pharmacology:
Our Technology
 
 

theraTRACE

Melior Pharmaceuticals

melior melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling

Melior Discovery partnering with us

 
   

Melior Discovery works collaboratively with its pharmaceutical and biopharmaceutical partners through the entire drug discovery and development process. The scope, goals and end-points of each study are discussed thoroughly and frequently with the client. This collaborative approach results in a customized program that is designed to meet the partner's specific needs.

Melior will work with clients to establish collaborations and partnerships that address specific stages of their drug discovery and development needs including:

• Early stage: Ideal when multiple leads must be narrowed down to a select few compounds suitable to move into development. With the potential reduction of false negatives, Melior's clients benefit from a greater likelihood of identifying compounds with greater efficacy in alternative indications.

• Late stage: Allows for co-development and risk sharing collaboration structures. In this scenario, Melior works with a partner's late stage drug candidate that may previously have failed in efficacy testing and utilizes the theraTRACESM platform to identify novel indications for the compound. In addition to the theraTRACESM discovery platform, Melior offers partners additional drug discovery capabilities, including individualized efficacy models and pharmacokinetic (PK) and maximum tolerated dose (MTD) evaluations to meet the diverse drug development needs of its partners.

For more information about our own development programs, please visit www.meliorpharmaceuticals.com.

For additional information, contact:
Andrew G. Reaume
President and CEO, Co-Founder
(610) 280-0633 ext. 239

Back to top of page